| abstract |
The present invention provides a variety of medical conditions and conditions associated with SLE, such as cutaneous lupus (disc-shaped), joint, lung and kidney systemic lupus, among others disclosed elsewhere herein, Tyrosine 175 is replaced by leucine (Y175L CRP) or leucine 176 for the treatment of blood conditions such as hemolytic anemia and low lymphocyte count, lymphadenopathy, and CNS effects such as memory loss, stroke and psychosis Relates to the use of mutant CRP molecules in which is replaced by glutamic acid (L176E CRP). In another aspect of the invention, a reduced likelihood of developing a patient at risk for developing a medical condition or condition associated with SLE is a further aspect of the invention. The present invention relates to the use of mutant Y175L CRP or L176E CRP in the treatment of many disease states or conditions that occur secondarily due to SLE of systemic lupus. The invention also relates to the treatment of immune thrombocytopenic purpura. Also disclosed are pharmaceutical compositions based on these mutant CRP molecules. |